908852-26-6

Basic information

• Product Name: C₃₅H₃₉ClN₂O₈
• Synonyms: C₃₅H₃₉ClN₂O₈
• CAS NO: 908852-26-6
• Molecular Weight: 651.156
• Mol File: 908852-26-6.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: C₃₅H₃₉ClN₂O₈(CAS DataBase Reference)
• NIST Chemistry Reference: C₃₅H₃₉ClN₂O₈(908852-26-6)
• EPA Substance Registry System: C₃₅H₃₉ClN₂O₈(908852-26-6)

Safety Data

• Hazardous Substances Data: 908852-26-6(Hazardous Substances Data)

Upstream product

• 16590-41-3 Naltrexone 
• 34841-39-9 bupropion 
• 34841-35-5 3'-chloro-propiophenone 
• 913728-76-4 3-tert-butyl-5-(3-chlorophenyl)-4-methyloxazolin-2-one 
• 913728-79-7 5-(3-chlorophenyl)-3-[2-(chlorocarbonyloxy)-1,1-dimethylethyl]-4-methyloxazolin-2-one 
• 49625-89-0 β-naltrexol 
• 34911-51-8 2-bromo-3'-chloropropiophenone 

Downstream Products

• 357399-43-0 (2R,3R)-2-(-3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol 
• 49625-89-0 β-naltrexol 

Relevant articles and documents

Enhancing transdermal delivery of opiod antagonists and agonistis using codrugs links to bupropion or hydroxybupropion

The present invention is directed to novel codrugs comprising bupropion or hydroxybupropion and an opioid antagonist or an opioid agonist joined together by chemical bonding. The codrugs provide a significant increase in the transdermal flux across human skin, as compared to the basic opioid antagonist or opioid agonist.